NN 8210

Drug Profile

NN 8210

Alternative Names: Anti-C5aR-215; NN-8210; NNC-0215-0384

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Oct 2014 Novo Nordisk completes a phase I trial in Rheumatoid arthritis in Germany, Hungary, Poland and Russia (NCT01955603)
  • 02 Sep 2014 Discontinued - Phase-I for Rheumatoid arthritis in Germany (IV, SC)
  • 02 Sep 2014 Discontinued - Phase-I for Rheumatoid arthritis in Hungary, Poland and Russia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top